Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 3Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Amyloidosis 1

Interventions

Cisplatin 55Carboplatin 49pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11Sunitinib 10Platinum 10130-nm albumin-bound paclitaxel 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Biological Assay × Clear all
NCT05642195 2026-05-27

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡